Navigation Links
Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
Date:4/7/2013

SAN DIEGO and FOUNTAIN VALLEY, Calif., April 8, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE) and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq™) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th). IGDRASOL is a privately-held company for which STI was granted an irrevocable option right to acquire.  The two companies' combined pipeline features an oncology franchise of potential products with Phase 2/3 data for multiple solid tumor indications as well as two synergistic drug discovery and development platforms, namely the G-MAB® human antibody library and MABiT™, a proprietary technology to generate antibody formulated drug conjugates (AfDC).

Cynviloq™ (or IG-001) is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries as Genexol-PM®. Cynviloq™ has completed Phase 1 or 2 trials in MBC, NSCLC, pancreatic cancer, ovarian cancer and bladder cancer in the US and/or non-US. IGDRASOL is preparing for an "End of Phase 2" meeting with the U.S. Food & Drug Administration (FDA) targeted for the first half of 2013 regarding Cynviloq™.  As an injectable nanoparticle formulation of paclitaxel, Cynviloq™ is potentially eligible for approval via FDA's 505(b)(2) regulatory pathway versus albumin-bound paclitaxel (nab-paclitaxel; Abraxane®) in its currently approved metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC) indications.

IG-004 (formerly known as TOCOSOL® paclitaxel) is a TPGS-based emulsion of paclitaxel, which was recently acquired from
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
2. Sorrento Therapeutics Awarded Third Phase I STTR Grant
3. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
4. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
5. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
6. Autoinjectors to 2018 - Devices, Therapeutics, Markets, Strategies and Prospects
7. ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"
8. Arno Therapeutics, Inc. Appoints Randy Thurman to the Board of Directors
9. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)
10. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
11. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 About Duchenne muscular ... disease, which generally affects the male population. It ... The disease is caused due to mutations in ... of production of dystrophin (a protein essential for ... of dystrophin weakens muscle function, causes loss of ...
(Date:9/2/2015)...  Array BioPharma Inc. (Nasdaq: ARRY ) ... Ron Squarer , will present at the Wells ... is welcome to participate in the conference through ... Fargo Securities Healthcare ConferencePresenter: Ron Squarer, Chief Executive ... a.m. Eastern Time Webcast: www.arraybiopharma.com   ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 About ... is a malignant condition characterized by increased production of ... affects B-lymphocytes and then it can spread to other ... at later stages because of the slow buildup of ... the malignancy spreads to the spleen, liver, and lymph ...
Breaking Medicine Technology:Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3
... Xlumena, Inc., a privately-held provider of innovative technology ... that it has received CE Mark approval for its ... system that enables exchange-free access, tract dilation and delivery ... NAVIX will join the AXIOS Stent and Delivery System ...
... The Chinese Biopharmaceutical Association-USA (CBA) successfully held its 16 ... US.   With the theme of ... the conference drew nearly 500 attendees with ... exhibited at the conference, including Chinese leading biotech parks, ...
Cached Medicine Technology:Xlumena Receives CE Mark for NAVIX™, Second Product to Enter European Market 2Chinese Biopharmaceutical Association Successfully Holds 16th Annual Conference 2Chinese Biopharmaceutical Association Successfully Holds 16th Annual Conference 3
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... The ... by using a complex of the Cas9 nuclease with either a chimeric single guide ... (tracrRNA)). The ability of any given guide RNA (sgRNA or crRNA) to create a ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... According to an article published ... Governor Jerry Brown that aims to do away with grand juries in cases meant to ... Passed as a direct response to grand jury decisions in Ferguson and New York City ...
(Date:9/2/2015)... FL (PRWEB) , ... September 02, 2015 , ... ... Amgen’s Blincyto® (blinatumomab) – in the news recently following a decision by the ... Medicare patients – is likely to average approximately $71,000 or roughly 40% of ...
(Date:9/2/2015)... ... September 02, 2015 , ... RxNT , an innovative ... its enhanced, cloud-based mobile ePrescribing application. The release of this enhanced iPhone app ... A leader in health technology, RxNT was one of the first to build ...
(Date:9/2/2015)... ... 02, 2015 , ... Density measurement is used in many ... handling makes density measurements more efficient and error-free. The new METTLER TOLEDO video ... and the advantages compared to manual sample handling. , The Evolution of Density ...
Breaking Medicine News(10 mins):Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3
... Year has a University of Cincinnati professor sharing his ... a new location. Randall Cottrell, a UC professor of ... Criminal Justice, and Human Services (CECH), is spending the ... Hangzhou, China. He says he is one of only ...
... with early rheumatoid arthritis (RA) who are current smokers were ... tumor necrosis factor (TNF) inhibitors than those who never smoked. ... patients who smoked in the past did not experience a ... appear in the January 2011 issue of Arthritis & ...
... TUCSON, Ariz. (January 4, 2011) -- Cumbersome glaucoma tests ... history thanks to a home test developed by an ... hand-held instrument involving a system of micro-force sensors, specially ... by researchers at the UA College of Engineering. The ...
... and referring clinicians frequently use portable media (CDs, DVDs) ... centers, including magnetic resonance imaging (MRI) and computed tomography ... of these portable media exist, according to a study ... the American College of Radiology ( www.jacr.org ). ...
... MONDAY, Jan. 3 (HealthDay News) -- Post-traumatic stress disorder ... emotional and cognitive problems -- while those who suffer ... to encounter symptoms over the long haul, a new ... been deployed to Operation Enduring Freedom and Operation Iraqi ...
... A five-year, $16-million grant from the National Cancer Institute ... at Albert Einstein College of Medicine of ... and Academic Medical Center for Einstein. The research ... Einstein, that comprise the Texas Center for Cancer Nanomedicine ...
Cached Medicine News:Health News:Fulbright Award has UC educator examining health challenges in China 2Health News:Current smokers with early rheumatoid arthritis less responsive to TNF inhibitors, methotrexate 2Health News:New glaucoma test allows earlier, more accurate detection 2Health News:Study finds problems with reviewing medical images from portable media 2Health News:Soldiers' PTSD Tied to Lasting Psychosocial Effects 2Health News:Einstein-Montefiore researcher will test nanoparticles against pancreatic cancer 2
... This double ended instrument was designed to ... up to one year postoperatively. The curved ... surgeon to lift the edge and then ... is used to smooth and reposition the ...
Smaller than the kuglen hook, this manipulator offers excellent grasping or lifting of the nucleus. Blunt finger-like 0.5 mm two-prong tip. Round knurled handle with dull finish. Angled....
This double ended instrument was designed for delineating and lifting the corneal flap of previously performed lamellar refractive surgery cases....
Short, narrow paddle angled 45 degree inserts through the side port stab incision and is ideal for effective manipulation of the lens during anterior chamber phacoemulsification....
Medicine Products: